Juel Chowdhury
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Juel Chowdhury has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah Abass
University of Alberta, 8-130 Clinical Sciences Building, 11350 83 Ave NW, Edmonton, AB, T6G2G3, Canada, 1 7804927002, 1 7804926088
1 shared publication - Angela Lim Fung
The Hospital for Sick Children
1 shared publication - Carrie Ye
McCaig Institute for Bone and Joint Health, Cumming School of Medicine, University of Calgary , Calgary AB
1 shared publication - Claire E. H. Barber
Department of Community Health Sciences Cumming School of Medicine, University of Calgary Calgary Alberta Canada
1 shared publication - Daniel C. Baumgart
Division of Gastroenterology and Hepatology, University of Alberta , Edmonton, Alberta
1 shared publication - Daniela Garcia Orellana
University of Alberta, 8-130 Clinical Sciences Building, 11350 83 Ave NW, Edmonton, AB, T6G2G3, Canada, 1 7804927002, 1 7804926088
1 shared publication
Latest Publications
- Open Access
- 8 April 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28 (1) , e87057
The Alberta Quality Assessment Tool: Risk of Bias (AQAT:RoB) for the Evaluation of Medical Large Language Model Question-Answer Studies: Development and Pilot Validation
Background: Despite the transformative potential of large language models (LLMs) in health care, the rapid development of these tools has outpaced their rigorous evaluation. While artificial intelligence–specific reporting guidelines have been developed to address standardized reporting of artificial intelligence studies, there is currently no specific tool available for risk of bias assessment of LLM question-answer (QA) studies. Existing risk-of-bias tools for medical research are not well suited to the unique challenges of evaluating LLM-QA studies, which creates a critical gap in assessing their safety and effectiveness. Objective: This study aims to develop the Alberta Quality Assessment Tool: Risk of Bias (AQAT:RoB) for LLM-QA studies to systematically evaluate the validity and risk of bias in LLM-QA studies. Methods: We conducted 2 literature reviews. The first was on quality assessment tools for LLM-QA studies, and the second was on LLM-QA studies, which informed the first draft of the AQAT:RoB. The draft AQAT:ROB was further refined through a prespecified iterative process of modified Delphi, consensus meeting, and validation. The first Delphi process occurred between May 1 and May 20, 2025, and the first consensus meeting was held on May 22. The first round of validation was completed by 4 evaluators, who were not part of the consensus meeting, on 16 randomly selected studies. As this first round of validation surpassed our a priori threshold of ≥80% agreement and a Cohen κ of ≥0.61 between evaluators, no further rounds of development and validation were undertaken. A second Delphi process occurred between February 20 and February 23, 2026, to vote on postpilot changes in response to peer review. Results: The AQAT:RoB consists of 5 high-level domains (Questions, Reference Answers, LLM Answers, Evaluators, Outcomes). These domains are subdivided into 9 subdomains. Each subdomain includes at least one “Support for Judgment” and at least one “Type of Bias” and is to be rated “low,” “high,” or “unclear” for risk of bias. A pilot evaluation was completed by internal validators who were not part of the consensus discussion and were asked to complete the AQAT:RoB form for each assigned study. Each of the 16 studies was evaluated by 2 evaluators independently. Pilot validation showed a percent agreement of 86.1% and a Cohen κ of 0.70 between assessors. Conclusions: The AQAT:RoB demonstrates promising initial reliability for assessing the validity or risk of bias in LLM-QA studies. The tool will benefit from future refinements, external validation, and periodic updates to keep pace with evolving technology.
- 8 April 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28 (1) , e87057
Open AccessThe Alberta Quality Assessment Tool: Risk of Bias (AQAT:RoB) for the Evaluation of Medical Large Language Model Question-Answer Studies: Development and Pilot Validation
Background: Despite the transformative potential of large language models (LLMs) in health care, the rapid development of these tools has outpaced their rigorous evaluation. While artificial intelligence–specific reporting guidelines have been developed to address standardized reporting of artificial intelligence studies, there is currently no specific tool available for risk of bias assessment of LLM question-answer (QA) studies. Existing risk-of-bias tools for medical research are not well suited to the unique challenges of evaluating LLM-QA studies, which creates a critical gap in assessing their safety and effectiveness. Objective: This study aims to develop the Alberta Quality Assessment Tool: Risk of Bias (AQAT:RoB) for LLM-QA studies to systematically evaluate the validity and risk of bias in LLM-QA studies. Methods: We conducted 2 literature reviews. The first was on quality assessment tools for LLM-QA studies, and the second was on LLM-QA studies, which informed the first draft of the AQAT:RoB. The draft AQAT:ROB was further refined through a prespecified iterative process of modified Delphi, consensus meeting, and validation. The first Delphi process occurred between May 1 and May 20, 2025, and the first consensus meeting was held on May 22. The first round of validation was completed by 4 evaluators, who were not part of the consensus meeting, on 16 randomly selected studies. As this first round of validation surpassed our a priori threshold of ≥80% agreement and a Cohen κ of ≥0.61 between evaluators, no further rounds of development and validation were undertaken. A second Delphi process occurred between February 20 and February 23, 2026, to vote on postpilot changes in response to peer review. Results: The AQAT:RoB consists of 5 high-level domains (Questions, Reference Answers, LLM Answers, Evaluators, Outcomes). These domains are subdivided into 9 subdomains. Each subdomain includes at least one “Support for Judgment” and at least one “Type of Bias” and is to be rated “low,” “high,” or “unclear” for risk of bias. A pilot evaluation was completed by internal validators who were not part of the consensus discussion and were asked to complete the AQAT:RoB form for each assigned study. Each of the 16 studies was evaluated by 2 evaluators independently. Pilot validation showed a percent agreement of 86.1% and a Cohen κ of 0.70 between assessors. Conclusions: The AQAT:RoB demonstrates promising initial reliability for assessing the validity or risk of bias in LLM-QA studies. The tool will benefit from future refinements, external validation, and periodic updates to keep pace with evolving technology.
- Open Access
- 14 November 2022
- Published by Scholar Publishing in British Journal of Healthcare and Medical Research
- Vol. 9 (6) , 50-60
Children with Asthma Exposed to COVID-19 Show a Decrease in Severity from Baseline: A Systematic Review from March 2020 to September 2022
Introduction: During the COVID-19 pandemic, children have been affected by SARS- CoV-2 infection, primarily affecting the respiratory system. Children with chronic respiratory diseases such as asthma, emphysema, and chronic bronchitis can experience an exacerbation of the preexisting conditions. The study's primary aim was to identify the severity of asthma in COVID-19-exposed children aged 4-12 years. Methods: We extracted the data from the PubMed database between March 2020 and September 2022. During the COVID-19 pandemic, PubMed-published articles involving children living with asthma aged 4-12 years were identified. The study included children who had tested positive for SARS-CoV-2 and excluded children with any other comorbidities. Results:We identified 169 PubMed- published articles and filtered 28 articles. Seven articles met the inclusion criteria and were included in the study. The children with asthma hospitalized owing to COVID-19 worldwide was 1% to 2.7%. Incidence was 12.8 times less frequent in children than in adults. Increased expression of the angiotensin-converting enzyme-2 gene in the bronchial epithelium of patients with type 2-low or T1-high asthma tended to have higher known risk factors for COVID-19. Among school-age children (N=277,285), 1.2% were hospitalized, 0.1% had intensive care unit admissions, and <0.1% died. Of those patients (hospitalized, ICU admissions, and those who died from COVID-19), all had at least one underlying medical condition, and 55% had chronic lung disease, including asthma. Conclusion: Most children with recurrent wheezing and asthma were well-controlled by their underlying asthma and did not require significant changes to their maintenance treatments. It concludes that children who tested positive for SARS-CoV-2 had fewer pediatric hospital admissions and attendance at urgent care settings. The reduction in asthma morbidities is due to improved adherence and decreased exposure to allergens and viral infections in children.
- 14 November 2022
- Published by Scholar Publishing in British Journal of Healthcare and Medical Research
- Vol. 9 (6) , 50-60
Open AccessChildren with Asthma Exposed to COVID-19 Show a Decrease in Severity from Baseline: A Systematic Review from March 2020 to September 2022
Introduction: During the COVID-19 pandemic, children have been affected by SARS- CoV-2 infection, primarily affecting the respiratory system. Children with chronic respiratory diseases such as asthma, emphysema, and chronic bronchitis can experience an exacerbation of the preexisting conditions. The study's primary aim was to identify the severity of asthma in COVID-19-exposed children aged 4-12 years. Methods: We extracted the data from the PubMed database between March 2020 and September 2022. During the COVID-19 pandemic, PubMed-published articles involving children living with asthma aged 4-12 years were identified. The study included children who had tested positive for SARS-CoV-2 and excluded children with any other comorbidities. Results:We identified 169 PubMed- published articles and filtered 28 articles. Seven articles met the inclusion criteria and were included in the study. The children with asthma hospitalized owing to COVID-19 worldwide was 1% to 2.7%. Incidence was 12.8 times less frequent in children than in adults. Increased expression of the angiotensin-converting enzyme-2 gene in the bronchial epithelium of patients with type 2-low or T1-high asthma tended to have higher known risk factors for COVID-19. Among school-age children (N=277,285), 1.2% were hospitalized, 0.1% had intensive care unit admissions, and <0.1% died. Of those patients (hospitalized, ICU admissions, and those who died from COVID-19), all had at least one underlying medical condition, and 55% had chronic lung disease, including asthma. Conclusion: Most children with recurrent wheezing and asthma were well-controlled by their underlying asthma and did not require significant changes to their maintenance treatments. It concludes that children who tested positive for SARS-CoV-2 had fewer pediatric hospital admissions and attendance at urgent care settings. The reduction in asthma morbidities is due to improved adherence and decreased exposure to allergens and viral infections in children.